Xue Charlie C L, An Xuedong, Cheung Thomas P, Da Costa Cliff, Lenon George B, Thien Frank C, Story David F
Division of Chinese Medicine, School of Health Sciences, World Health Organization Collaborating Centre for Traditional Medicine, RMIT University, Melbourne, VIC, Australia.
Med J Aust. 2007 Sep 17;187(6):337-41. doi: 10.5694/j.1326-5377.2007.tb01275.x.
To investigate the effectiveness and safety of acupuncture in persistent allergic rhinitis (PAR) DESIGN: Randomised, single-blind, sham-controlled trial conducted from May 2004 to February 2005.
80 patients with PAR (age, 16-70 years) were randomly assigned to receive real or sham acupuncture. After a 1-week baseline period, participants were treated twice weekly for 8 weeks and followed up for another 12 weeks.
Nasal obstruction, sneezing, rhinorrhoea and nasal itch were each self-assessed daily on a 5-point scale, and scores were aggregated weekly. The sum of the symptom scores (total nasal symptom score, TNSS) was also determined. A secondary outcome was use of PAR relief medication.
After 8 weeks' treatment, the weekly mean difference in TNSS from baseline was greater with real (-17.2; 95% CI, -24.6 to -9.8) than with sham acupuncture (-4.2; 95% CI, -11.0 to 2.7) (P = 0.01). The decrease in individual symptom score was also greater with real acupuncture for rhinorrhoea (P < 0.01) but not the other symptoms. At the end of follow-up, the greater difference in TNSS from baseline in the real acupuncture group was still apparent: real, -21.0 (95% CI, -29.1 to -12.9) versus sham, - 2.3 (95% CI, -10.2 to 5.6) (P = 0.001). Moreover, the differences from baseline in all four individual symptom scores were greater for the real than for the sham group (P < 0.05). Real and sham acupuncture were both well tolerated.
Our findings suggest that acupuncture is effective in the symptomatic treatment of PAR.
Australian Government Therapeutic Goods Administration CTN 034/2004.
探讨针灸治疗持续性变应性鼻炎（PAR）的有效性和安全性。
2004年5月至2005年2月进行的随机、单盲、假针刺对照试验。
80例PAR患者（年龄16 - 70岁）被随机分配接受真针刺或假针刺治疗。在为期1周的基线期后，参与者每周接受两次治疗，持续8周，并随访12周。
鼻塞、打喷嚏、流涕和鼻痒症状每天由患者自行采用5分制进行评估，每周汇总评分。计算症状评分总和（总鼻症状评分，TNSS）。次要观察指标为PAR缓解药物的使用情况。
治疗8周后，真针刺组TNSS较基线的每周平均差值为-17.2（95%可信区间，-24.6至-9.8），大于假针刺组的-4.2（95%可信区间，-11.0至2.7）（P = 0.01）。真针刺组流涕症状的个体症状评分下降幅度也更大（P < 0.01），但其他症状无此差异。随访结束时，真针刺组TNSS较基线的差异仍更显著：真针刺组为-21.0（95%可信区间，-29.1至-12.9），假针刺组为-2.3（95%可信区间，-10.2至5.6）（P = 0.001）。此外，真针刺组所有四个个体症状评分较基线的差异均大于假针刺组（P < 0.05）。真针刺和假针刺的耐受性均良好。
我们的研究结果表明，针灸在PAR的症状性治疗中是有效的。
澳大利亚政府治疗用品管理局CTN 034/2004。
